Presenting new and updated data from HGB-205 study in beta-thalassemia major and severe sickle cell disease, including first patient with sickle cell disease ever treated with gene therapy
Company to host investor call on
“The early data included in our abstract provide further validation for
our approach and important insights into the safety and mechanism of
action of LentiGlobin in both beta-thalassemia and sickle cell disease,”
Abstract Highlights (Data as of
- Beta-thalassemia: Beta-thalassemia major subjects (1201 and 1202) remained transfusion independent at 14 months and 11 months, respectively
Sickle Cell Disease: This subject (1204) entered the trial
receiving chronic transfusions and began the process of being weaned
from transfusions after day 37, receiving the last transfusion on day
Increasing production of HbAT87Q; the first-ever SCD
patient treated with gene therapy (subject 1204) had a HbAT87Q
level of 24% at 4.5 months follow up, compared to an HbAT87Q
level of 9.6% at three months post-transplant
- Note that this subject did not engraft until after month one, so their level of HbAT87Q production at months three and 4.5 are actually months two and 3.5, after engraftment
- At 4.5 months follow up, total anti-sickling hemoglobin (HbAT87Q + HbF) was 31.6%
- Subject 1204 has not had any hospitalizations for SCD-related complications post-transplant
- Increasing production of HbAT87Q; the first-ever SCD patient treated with gene therapy (subject 1204) had a HbAT87Q level of 24% at 4.5 months follow up, compared to an HbAT87Q level of 9.6% at three months post-transplant
- Safety: No subject has experienced a drug product-related adverse event, and integration site analyses demonstrate highly polyclonal reconstitution without clonal dominance
Based on historical clinical observations in patients with SCD, bluebird bio believes that individuals who achieve ≥ 30 percent of anti-sickling hemoglobin (HbAT87Q + HbF) have the potential to reduce or eliminate the serious and life-threatening events associated with SCD.
The abstract is now available online on the EHA conference website. Information contained in the abstract reflects data available as of February 2015. Details of bluebird bio’s presentation are as follows:
Title: Outcomes of Gene Therapy for B-Thalassemia Major and
Severe Sickle Cell Disease via Transplantation of Autologous
Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta
Abstract Code: S466
Session Name: Gene therapy, cellular immunotherapy and vaccination
Oral Presentation Time: 11:30 -
Location: Reed Messe Vienna, Room Stolz 2
Investor Conference Call and Webcast Information
bluebird bio will host a conference call and webcast on June 15, 2015 at
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of beta-thalassemia major; a single-center Phase 1/2 study in France (HGB-205) for the treatment of beta-thalassemia major or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of sickle cell disease (HGB-206). bluebird bio also has a preclinical CAR T immuno-oncology program in collaboration with Celgene Corporation, as well as discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of, and anticipated milestones related to the Company’s product candidates, including LentiGlobin. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, the risk of a delay in the enrollment of patients in the Company’s clinical studies, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that our collaboration with
Source: bluebird bio, Inc.
bluebird bio, Inc.
Jim DeTore, 339-499-9355
Chief Financial Officer
Pure Communications, Inc.
Dan Budwick, 973-271-6085